During the past decade, SCRI-CCCIT GesmbH ( Site 0371) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "SCRI-CCCIT GesmbH ( Site 0371)" are "Prostatic Neoplasms" (2 trials). Many other conditions were trialed in "SCRI-CCCIT GesmbH ( Site 0371)" in a lesser frequency.

Most popular intervention types in "SCRI-CCCIT GesmbH ( Site 0371)" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (2 trials), "Prednisone" (2 trials), "Abiraterone acetate" (1 trials), "Dexamethasone" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "SCRI-CCCIT GesmbH ( Site 0371)" are 2 trials for "Male" genders.

Currently, there are NaN active trials in "SCRI-CCCIT GesmbH ( Site 0371)". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in SCRI-CCCIT GesmbH ( Site 0371), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in SCRI-CCCIT GesmbH ( Site 0371), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".